NCT04195399 2026-04-15
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
Children's Oncology Group
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT05879146 2026-04-13
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07170644 2026-04-06
A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
SpringWorks Therapeutics, Inc.
Phase 2 Active not recruiting
NCT05090566 2026-02-23
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Pfizer
Phase 2 Active not recruiting
NCT05348356 2025-12-15
Nirogacestat in Ovarian Granulosa Cell Tumors
SpringWorks Therapeutics, Inc.
Phase 2 Completed
NCT04126200 2025-11-06
DREAMM5
GlaxoSmithKline
Phase 2 Active not recruiting
NCT05949099 2025-09-08
Study of Cryoablation and Nirogacestat for Desmoid Tumor
Stanford University
Phase 2 Recruiting
NCT01981551 2024-02-06
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02109445 2019-01-10
Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies
Pfizer
Phase 2 Terminated
NCT02299635 2019-01-08
A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
Pfizer
Phase 2 Terminated
NCT02338531 2016-04-29
RHEA
Jules Bordet Institute
Phase 2 Withdrawn
NCT02137564 2015-07-23
Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma
AIDS Malignancy Consortium
Phase 2 Withdrawn